Psychopharmacology Bulletin Featured in EBSCO’s Latest Edition of New & Notable

By |2018-03-23T15:32:55-07:00March 23rd, 2018|MedWorks, We Know Psychiatry|

We are excited to announce that MedWorks Media's flagship journal, Psychopharmacology Bulletin, has been featured in EBSCO's latest issue of New & Notable. MedWorks Media (Psychopharmacology Bulletin) has partnered with EBSCO Information Services for over 15 years. EBSCO Information Services provides a complete and optimized research solution comprised [...]

Smoking Cessation Drug May Boost Cognition in Schizophrenia

By |2017-03-22T17:58:08-07:00March 22nd, 2017|MedWorks, We Know Psychiatry|

In findings reported in a letter to the editor published online March 10 in Schizophrenia Research and reported by Medscape Medical News, the smoking cessation drug varenicline (Chantix) appears to enhance cognition in nonsmoking individuals with and those without schizophrenia. The results also showed that the drug reduced the cognitive [...]

FDA Clears Chewable Methylphenidate (QuilliChew) for ADHD

By |2015-12-14T14:33:45-08:00December 14th, 2015|MedWorks, We Know Psychiatry|

The US Food and Drug Administration (FDA) has approved a chewable tablet form of extended-release methylphenidate (QuilliChew ER, Pfizer Inc) for attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years and older, the company announced today. The chewable product will be available in tablet form in strengths of 20, 30, and [...]

ER Naltrexone Halts Opioid Relapse in At-Risk Population

By |2015-12-14T14:28:25-08:00December 14th, 2015|MedWorks, We Know Psychiatry|

HUNTINGTON BEACH, California ― Results of a large, multicenter, randomized trial show that extended-release (ER) naltrexone (Vivitrol, Alkermes, Inc) can effectively prevent opioid relapse among a particularly vulnerable population: adults involved in the criminal justice system. "Extended-release naltrexone is better known now, but this study began prior to its approval [...]